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Gout is a common inflammatory arthritis resulting 
from the crystallisation of uric acid within joints. 
It is often, but not always, associated with 
hyperuricaemia. It is common, affecting around 
2% of men aged over 30 years and women aged 
over 50 years, and its prevalence appears to 
be increasing.1 In Australian general practice, it is 
in the top 20 of chronic diseases managed 
and is seen at a rate of six per 1000 general 
practitioner encounters.2
	
Treatment	 options	 for	 acute	 gout	 include	 nonsteroidal	




	 Schlesinger	 et	 al5	 performed	 a	 systematic	 review	 to	
assess	 the	 efficacy	 and	 adverse	 effects	 of	 colchicine	
compared	 to	 placebo	 or	 compared	 to	 other	 acute	 gout	




While	 colchicine	 has	 demonstrated	 its	 efficacy	 as	 a	
treatment	 of	 acute	 gout	 at	 the	 standard	 dosage	 of	 1	
mg	 orally,	 followed	 by	 0.5	mg	 2	 hourly,	 the	 high	 levels	
of	 gastrointestinal	 side	 effects	 limits	 its	 use	 at	 those	
doses.	The	 only	 evidence	 to	 support	 the	 use	 of	 lower	
doses	 is	 weak	 –	 coming	 from	 case	 reports	 –	 but	
this	 remains	 an	 option	 in	 patients	 in	 whom	 other	
therapies	 are	 contraindicated.	 Further	 research	 is	
required	 to	 determine	 the	 lowest	 dose	 of	 colchicine	
that	 will	 adequately	 treat	 acute	 gout,	 and	 to	 directly	
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This series of articles facilitated by the Cochrane Musculoskeletal Group (CMSG) aims to place the 
findings of recent Cochrane musculoskeletal reviews in a context immediately relevant to general 
practitioners. This article considers the place of colchicine in the management of acute gout.
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Table 2. Putting evidence into practice 
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